Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
73 hedge funds and large institutions have $78.5M invested in Cellular Biomedicine Group, Inc. in 2020 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 3 closing their positions.
933% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 3
62% more funds holding
Funds holding: 45 → 73 (+28)
50% more capital invested
Capital invested by funds: $52.2M → $78.5M (+$26.3M)
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
58% less call options, than puts
Call options by funds: $492K | Put options by funds: $1.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.96M |
| 2 |
GCL
Glazer Capital LLC
New York
|
+$3.4M |
| 3 |
Man Group
London,
United Kingdom
|
+$2.36M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$2.32M |
| 5 |
WIC
Water Island Capital
New York
|
+$2.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$8.92M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$2.04M |
| 3 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
-$810K |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
-$732K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$495K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Simplex Trading
Chicago,
Illinois
| – | +$6.1K | +363 | New |
|
CBMG Hedge Fund Activity: Q3 2020 in Review
73 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q3 2020, worth a combined $78.5M — up 50% from $52.2M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CBMG positions and 3 closed out — a net gain of 28 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was Candriam SCA, opening a new position worth an estimated $3.96M. The largest seller was ARK Investment Management, cutting an estimated $8.92M.
- 73 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q3 2020, up from 45 in Q2 2020.
- Funds reported $78.5M of Cellular Biomedicine Group, Inc. stock for Q3 2020, up 50% quarter-over-quarter.
- 31 funds opened new Cellular Biomedicine Group, Inc. positions in Q3 2020 and 3 closed out, a net change of +28 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q3 2020 was Candriam SCA, an estimated $3.96M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q3 2020 was ARK Investment Management, an estimated $8.92M sold.
Based on aggregated 13F filings for Q3 2020.